Middleton & Co. Inc. MA Has $9.24 Million Stock Position in Eli Lilly and Company $LLY

Middleton & Co. Inc. MA boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1,693.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,107 shares of the company’s stock after purchasing an additional 11,432 shares during the period. Middleton & Co. Inc. MA’s holdings in Eli Lilly and Company were worth $9,238,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of LLY. Laurel Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after buying an additional 11,537,661 shares during the last quarter. Norges Bank bought a new stake in Eli Lilly and Company during the second quarter worth $8,827,714,000. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 1.5% in the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after acquiring an additional 1,183,038 shares during the last quarter. Franklin Resources Inc. lifted its stake in Eli Lilly and Company by 13.4% in the second quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock valued at $3,715,913,000 after acquiring an additional 564,736 shares during the last quarter. Finally, Canada Pension Plan Investment Board grew its position in shares of Eli Lilly and Company by 87.2% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock valued at $898,238,000 after acquiring an additional 536,679 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LLY. Guggenheim dropped their target price on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a report on Tuesday. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. National Bankshares set a $1,286.00 price objective on Eli Lilly and Company in a research report on Monday, December 1st. Daiwa Capital Markets set a $1,230.00 target price on Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Finally, HSBC reissued a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Five investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $1,174.61.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA grants Breakthrough Therapy designation to Lilly’s sofetabart mipitecan for certain platinum?resistant ovarian cancers — a meaningful validation for Lilly’s oncology pipeline that diversifies revenue beyond GLP?1 drugs and could accelerate development/partnering value. Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation
• Positive Sentiment: Phase results: Lilly’s Taltz combined with Zepbound showed superior results in a landmark psoriatic?arthritis trial — suggests label expansion and additional commercial upside for existing franchises. Eli Lilly’s Taltz and Zepbound combo delivers superior results
• Positive Sentiment: Analyst/media bullishness: Several outlets (MarketBeat, The Motley Fool) highlight Lilly as a top play in 2026 because Zepbound and Mounjaro drive rapid growth and the company has late?stage assets (Alzheimer’s, oncology, CV) that could sustain upside. That framing supports multiple expansion narratives. 3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026
• Positive Sentiment: Longer?term growth thesis reinforced: The Motley Fool argues 2026 could be “the year of Eli Lilly,” pointing to the company’s weight?loss portfolio (recent quarter ~ $10B) and upcoming catalysts — a narrative that attracts growth investors. Prediction: 2026 Will Be the Year of Eli Lilly
• Neutral Sentiment: Analyst note: Guggenheim trimmed its price target slightly (from $1,163 to $1,161) but kept a “buy” rating — a minor technical change that maintains analyst bullishness and implies continued upside from current levels. LLY price target lowered by Guggenheim
• Neutral Sentiment: Takeover speculation calmed: Reports that Lilly might bid for Abivax circulated, but Abivax’s CEO dismissed the rumors as “noise,” removing an M&A upside narrative (so neutral-to-cooling for any takeover-driven pop). Abivax CEO dismisses ‘noise’ around rumored Eli Lilly bid
• Neutral Sentiment: Industry comparison pieces (Zacks, Blockonomi) reiterate Lilly’s strength from Mounjaro/Zepbound and note an oral GLP?1 near approval — these are context pieces that support the growth story but also flag competitive dynamics to watch. Which Pharma Stock Stands Taller Right Now: LLY or PFE?
• Negative Sentiment: Competitive risk: Novo Nordisk’s new oral Wegovy pill showed very fast initial prescriptions after launch, and analysts note rising competition as oral formulations and other entrants scale — a development that could pressure Lilly’s market share and future growth if its oral GLP?1 underperforms or is delayed. Eli Lilly vs. Novo Nordisk: Which Stock Has the Edge Right Now?

Eli Lilly and Company Trading Up 0.2%

Shares of NYSE:LLY opened at $1,040.95 on Wednesday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The business has a 50 day moving average of $1,053.86 and a 200-day moving average of $875.14. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock has a market cap of $984.09 billion, a PE ratio of 50.93, a P/E/G ratio of 0.78 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is 29.35%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.